General Information

Suplatast Impurities and Suplatast 

Daicel Pharma offers Suplatast impurities like 1-(4-aminophenoxy)-3-ethoxypropane-2-ol, N-(4-(3-ethoxy-2-hydroxypropoxy), phenyl)-3-(methylthio)propanamide, N-(4-(3-ethoxy-2-hydroxypropoxy)phenyl), acrylamide and N-(4-(3-ethoxy-2-hydroxypropoxy)phenyl)-3-hydroxypropanamide, etc. The impurities are of utmost importance when assessing the quality, stability, and biological safety of the active pharmaceutical ingredient Suplatast. Daicel Pharma specializes in synthesizing custom Suplatast impurities to meet precise customer specifications. With a commitment to worldwide delivery, Daicel Pharma ensures that customers receive the synthesized Suplatast impurities promptly and reliably.

Suplatast [CAS: 94055-75-1] is a medicine primarily used to treat allergic diseases, including asthma, atopic dermatitis, and allergic rhinitis. It is classified as an immunomodulator and suppresses the immune response associated with allergic reactions.

Suplatast: Use and Commercial Availability  

Suplatast, an innovative immunomodulator, can restore the equilibrium in the Th1/Th2 immune response and demonstrates notable clinical effectiveness in managing bronchial asthma (BA). Suplatast treats BA, allergic rhinitis, and atopic dermatitis.

Suplatast is available under Tosilart, IPD-1151T, etc., which contains the active ingredient, Suplatast.

Suplatast Structure and Mechanism of Action

The chemical name of Suplatast is [3-[[4-(3-Ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethylsulfonium. Its chemical formula is C₁₆H₂₆NO₄S, and its molecular weight is approximately 328.4 g/mol.

Suplatast inhibits the production of IgE, impeding cytokine production and suppressing eosinophils associated with allergies.

Suplatast Impurities and Synthesis

During the synthesis and storage of Suplatast¹, impurities can arise, including related substances, degradation products, and residual solvents. It is essential to carefully monitor and control these impurities to ensure the medication’s safety, efficacy, and overall quality.

Daicel Pharma offers a comprehensive Certificate of Analysis (CoA) for impurity standards such as – 1-(4-aminophenoxy)-3-ethoxypropane-2-ol, N-(4-(3-ethoxy-2-hydroxypropoxy), phenyl)-3-(methylthio)propanamide, N-(4-(3-ethoxy-2-hydroxypropoxy)phenyl), acrylamide and N-(4-(3-ethoxy-2-hydroxypropoxy)phenyl)-3-hydroxy propenamide, etc. These impurities form in compliance with current Good Manufacturing Practices (cGMP). The CoA includes detailed characterization data, such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity, providing a thorough understanding of the impurity profile. Upon request, Daicel can also provide 13C-DEPT data for further characterization.

Furthermore, Daicel Pharma possesses the technical expertise to synthesize any unknown impurities or degradation products of Suplatast. Daicel Pharma also provides labeled compounds specifically designed to assess the effectiveness of generic versions of Suplatast. Daicel Pharma offers highly pure Deuterated Suplatast Tosilate, the deuterated-labeled standard of Suplatast for bioanalytical research and Bioavailability/Bioequivalence (BA/BE) studies.